[go: up one dir, main page]

NO20060145L - Substituerte indazolyl (indolyl) maleimidderivater som kinase inhibitorer - Google Patents

Substituerte indazolyl (indolyl) maleimidderivater som kinase inhibitorer

Info

Publication number
NO20060145L
NO20060145L NO20060145A NO20060145A NO20060145L NO 20060145 L NO20060145 L NO 20060145L NO 20060145 A NO20060145 A NO 20060145A NO 20060145 A NO20060145 A NO 20060145A NO 20060145 L NO20060145 L NO 20060145L
Authority
NO
Norway
Prior art keywords
sub
kinase inhibitors
kinase
indolyl
compounds
Prior art date
Application number
NO20060145A
Other languages
English (en)
Inventor
Bruce E Maryanoff
Han-Cheng Zhang
Hong Ye
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of NO20060145L publication Critical patent/NO20060145L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • AIDS & HIV (AREA)

Abstract

Foreliggende oppfinnelse angår nye indazolyl-substituerte pyrrolinforbindelser med formel (I): R2 er valgt fra gruppen som består av -C1-8 alkyl-Z, -C2-8 alkenyl-Z og -C2-8 alkynyl-Z; hvori -C1-8 alkyl-Z, -C2-8 alkenyl-Z og -C2-8 alkynyl-Z og Z er en 5 til 6 leddet aromatisk monosyklisk heteroaryl ring som har fra 2 til 4 heteroatomer. Disse forbindelser er anvendelige som kinase eller dual-kinase inhibitorer, fremgangsmåte for fremstilling av slike forbindelser og fremgangsmåte for behandling eller lindring av en kinase eller dual-kinasemediert forstyrrelse.
NO20060145A 2003-06-13 2006-01-10 Substituerte indazolyl (indolyl) maleimidderivater som kinase inhibitorer NO20060145L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47851603P 2003-06-13 2003-06-13
PCT/US2004/017375 WO2005000836A1 (en) 2003-06-13 2004-06-01 Substituted indazolyl(indolyl)maleimide derivatives as kinase inhibitors

Publications (1)

Publication Number Publication Date
NO20060145L true NO20060145L (no) 2006-03-07

Family

ID=33551833

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20060145A NO20060145L (no) 2003-06-13 2006-01-10 Substituerte indazolyl (indolyl) maleimidderivater som kinase inhibitorer

Country Status (22)

Country Link
US (1) US7439363B2 (no)
EP (1) EP1654255B1 (no)
JP (1) JP2007500748A (no)
KR (1) KR20060021890A (no)
CN (1) CN1832940A (no)
AT (1) ATE406365T1 (no)
AU (1) AU2004251178A1 (no)
BR (1) BRPI0411366A (no)
CA (1) CA2529353A1 (no)
CO (1) CO5650246A2 (no)
CR (1) CR8148A (no)
DE (1) DE602004016174D1 (no)
EA (1) EA200600032A1 (no)
EC (1) ECSP056222A (no)
ES (1) ES2311161T3 (no)
HR (1) HRP20050991A2 (no)
IL (1) IL172456A0 (no)
IS (1) IS8174A (no)
NO (1) NO20060145L (no)
RS (1) RS20050915A (no)
WO (1) WO2005000836A1 (no)
ZA (1) ZA200600294B (no)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1230434C (zh) 2000-12-08 2005-12-07 奥索-麦克尼尔药品公司 用作激酶抑制剂的吲唑基取代的吡咯啉化合物
AU2003225295A1 (en) * 2002-05-08 2003-11-11 Janssen Pharmaceutica N.V. Substituted pyrroline kinase inhibitors
DE60323749D1 (de) * 2002-06-05 2008-11-06 Janssen Pharmaceutica Nv Substituierte pyrroline als kinase inhibitoren
CA2520590A1 (en) * 2003-03-27 2004-11-04 Janssen Pharmaceutica, N.V. Substituted pyrroline kinase inhibitors
EP2258357A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
CA2620333A1 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
JP2009510085A (ja) * 2005-09-29 2009-03-12 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ キナーゼインヒビターとしての大型複素環式化合物
WO2007047978A2 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
JP2009536669A (ja) 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド アンジオテンシン調節による神経新生
KR101284836B1 (ko) 2006-05-25 2013-07-10 삼성전자주식회사 이동통신시스템에서 자원 할당 맵 구성 방법
CA2666193A1 (en) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, process for preparing them, medicaments comprising these compounds, and their use
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2008037266A1 (en) * 2006-09-25 2008-04-03 Universite Libre De Bruxelles Inhibitors of conventional protein kinase c isozymes and use thereof for treating inflammatory diseases
US8193236B2 (en) 2006-12-19 2012-06-05 Novartis Ag Indolylmaleimide derivatives processes for their production and pharmaceutical compositions
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
UY31968A (es) 2008-07-09 2010-01-29 Sanofi Aventis Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
MX2012001729A (es) 2009-08-26 2012-06-13 Sanofi Sa Nuevos hidratos cristalinos de fluoroglicosido heteroaromatico, productos farmaceuticos que comprenden estos compuestos, y su empleo.
RU2441000C2 (ru) * 2009-11-27 2012-01-27 Общество с ограниченной ответственностью "Молекулярные Технологии" 4-(1-(4-(4-метоксифенилтио)-2,5-диоксо-2,5-дигидро-1н-пирро-3-ил)-1н-индол-3-ил)бутилкарбамимидотиоат и способ его применения
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
ES2387359B1 (es) * 2011-02-25 2013-08-01 Consejo Superior De Investigaciones Científicas (Csic) Inhibidores de GSK-3 útiles en enfermedades neurodegenerativas, inflamatorias, cáncer, diabetes y en procesos regenerativos
EP2683702B1 (de) 2011-03-08 2014-12-24 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120058A1 (de) 2011-03-08 2012-09-13 Sanofi Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8895547B2 (en) 2011-03-08 2014-11-25 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120051A1 (de) 2011-03-08 2012-09-13 Sanofi Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120053A1 (de) 2011-03-08 2012-09-13 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683700B1 (de) 2011-03-08 2015-02-18 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
CN102344443A (zh) * 2011-07-15 2012-02-08 南开大学 点击化学合成开环马来酰亚胺类化合物及其在治疗疾病中的应用
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CN103622964B (zh) * 2013-12-04 2015-09-23 李强 Trigolutesins A在治疗或预防急性心衰药物中的应用
US10220408B2 (en) * 2016-09-12 2019-03-05 The Boeing Company Variable radius print head end effector
CN108586432B (zh) * 2018-05-31 2020-08-25 温州医科大学 一种3-(吲哚-5-基)-吲唑衍生物及其应用
US20220133740A1 (en) 2019-02-08 2022-05-05 Frequency Therapeutics, Inc. Valproic acid compounds and wnt agonists for treating ear disorders

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK75289A3 (en) 1988-02-10 1998-05-06 Hoffmann La Roche Substituted pyrroles, their use for producing a drug, and the drug on their base
GB8904161D0 (en) 1989-02-23 1989-04-05 Hoffmann La Roche Substituted pyrroles
US5624949A (en) 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
SE9603283D0 (sv) * 1996-09-10 1996-09-10 Astra Ab New compounds
CA2338866A1 (en) 1998-07-30 2000-02-10 Japan Tobacco Inc. Disubstituted maleimide compound and pharmaceutical use thereof
AU6111699A (en) 1998-10-08 2000-05-01 Smithkline Beecham Plc Novel method and compounds
CN1230434C (zh) * 2000-12-08 2005-12-07 奥索-麦克尼尔药品公司 用作激酶抑制剂的吲唑基取代的吡咯啉化合物
AU2003225295A1 (en) 2002-05-08 2003-11-11 Janssen Pharmaceutica N.V. Substituted pyrroline kinase inhibitors
DE60323749D1 (de) 2002-06-05 2008-11-06 Janssen Pharmaceutica Nv Substituierte pyrroline als kinase inhibitoren
KR20050008787A (ko) 2002-06-05 2005-01-21 얀센 파마슈티카 엔.브이. 키나제 저해제로서의 비스인돌릴-말레이미드 유도체
CA2520590A1 (en) 2003-03-27 2004-11-04 Janssen Pharmaceutica, N.V. Substituted pyrroline kinase inhibitors

Also Published As

Publication number Publication date
JP2007500748A (ja) 2007-01-18
ATE406365T1 (de) 2008-09-15
CA2529353A1 (en) 2005-01-06
AU2004251178A1 (en) 2005-01-06
ECSP056222A (es) 2006-04-19
US20050004201A1 (en) 2005-01-06
IL172456A0 (en) 2006-04-10
KR20060021890A (ko) 2006-03-08
IS8174A (is) 2005-12-09
CO5650246A2 (es) 2006-06-30
EA200600032A1 (ru) 2006-06-30
US7439363B2 (en) 2008-10-21
ZA200600294B (en) 2007-04-25
CR8148A (es) 2008-09-10
DE602004016174D1 (de) 2008-10-09
WO2005000836A1 (en) 2005-01-06
RS20050915A (sr) 2008-04-04
ES2311161T3 (es) 2009-02-01
EP1654255A1 (en) 2006-05-10
BRPI0411366A (pt) 2006-07-25
CN1832940A (zh) 2006-09-13
EP1654255B1 (en) 2008-08-27
HRP20050991A2 (en) 2006-09-30

Similar Documents

Publication Publication Date Title
NO20060145L (no) Substituerte indazolyl (indolyl) maleimidderivater som kinase inhibitorer
WO2009109991A3 (en) Novel hydrazide containing tyrosine kinase inhibitors
DK1362047T3 (da) Indazolylsubstituerede pyrrolinforbindelser som kinaseinhibitorer
GB0005357D0 (en) Compounds
YU84603A (sh) Novi inhibitori tirozin kinaze
DE60213609D1 (de) THIENOi2,3-döPYRIMIDINEDIONES ALS INHIBITOREN VON T-ZELLEN-PROLIFERATION
MA31574B1 (fr) Dérivés de pyrazole et leur utilisation comme inhibiteurs de raf
HUP0402376A2 (hu) Imidazol-4-karboxamid-származékok, előállításuk és az ezeket tartalmazó, elhízás kezelésére alkalmas gyógyszerkészítmények
ATE449099T1 (de) Derivate des 2-trifluormethyl-6-aminopurins als phosphodiesterase 4 inhibitoren
EP1534695A4 (en) tyrosine kinase inhibitors
NO911121D0 (no) Fremgangsmaate for fremstilling av nye skvalen-synetase-inhibitorer.
ATE403653T1 (de) Pyridin-substituierte furanderivate als raf- kinase inhibitoren
DE60221425D1 (de) Substituierte tetrazyklische pyprolochinolonderivate als phosphodiesterase-inhibitoren
WO2006063113A3 (en) Ureas as factor xa inhibitors
DE60336735D1 (de) Neue biologischaktive molekü le
NO20060963L (no) Nikotinamidderivater anvendelige som PDE4-inhibitorer
EA200970497A1 (ru) Производные пиррола, их получение и их применение в терапии
ATE419242T1 (de) Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren
ATE442354T1 (de) Pyrrolidinderivate als oxytocin antagonisten
IL166164A0 (en) 6-amino-1h-indazole and 4-aminobenzofuran compounds as phosphodiesterase 4 inhibitors
AU2003281220A1 (en) N-benzyl-3-phenyl-3-heterocyclyl-propionamide compounds as tachykinin and/ or serotonin reuptake inhibitors
MX2007015739A (es) Intermedios utiles en la sintesis de moduladores de alquilquinolina y alquilquinazolina cinasa y metodos relacionados de sintesis.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application